Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REM-422 in Relapsed/Refractory AML or Higher-Risk MDS
NCT06297941Phase 1Recruiting
- Sponsor
- Remix Therapeutics
- Start
- Apr 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of REM-422 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Remix Therapeutics. Primary endpoints: Treatment Emergent Adverse Events at 24 months and Maximum Tolerated Dose and/or Recommended Phase 2 Dose at 24 months. Started Apr 2024; status: recruiting.
02
Drugs
REM-422
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06297941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06297941.